Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29941280

Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2018 Aug
First author
Bisogno G

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Aug;19(8):1004-1006. doi: 10.1016/S1470-2045(18)30513-8.
    note
    Source null
    related pmid
    30102209
    relationship
    Comment in

Authors and identifiers

  1. name
    Bisogno G
    type
    Author
  2. name
    Jenney M
    type
    Author
  3. name
    Bergeron C
    type
    Author
  4. name
    Gallego Melcón S
    type
    Author
  5. name
    Ferrari A
    type
    Author
  6. name
    Oberlin O
    type
    Author
  7. name
    Carli M
    type
    Author
  8. name
    Stevens M
    type
    Author
  9. name
    Kelsey A
    type
    Author
  10. name
    De Paoli A
    type
    Author
  11. name
    Gaze MN
    type
    Author
  12. name
    Martelli H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bisogno G
    type
    Author
  2. name
    Jenney M
    type
    Author
  3. name
    Bergeron C
    type
    Author
  4. name
    Gallego Melcón S
    type
    Author
  5. name
    Ferrari A
    type
    Author
  6. name
    Oberlin O
    type
    Author
  7. name
    Carli M
    type
    Author
  8. name
    Stevens M
    type
    Author
  9. name
    Kelsey A
    type
    Author
  10. name
    De Paoli A
    type
    Author
  11. name
    Gaze MN
    type
    Author
  12. name
    Martelli H
    type
    Author
bibliography ids
  1. nci-bib-034977255fd16f1f5b25d19b
book metadata
content sha256
5e9675506a07e0668a98e72ceceb2dc2ed182a22e981f79b891ed16ab33874e3
document type
citation
dois
  1. 10.1016/S1470-2045(18)30337-1
electronic publication date
display
2018 Jun 22
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:29941280
immutable id
pubmed:29941280@5e9675506a07e0668a98e72ceceb2dc2ed182a22e981f79b891ed16ab33874e3
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
8
name
The Lancet. Oncology
nlm unique id
100957246
pages
1061-1071
volume
19
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2018 Aug;19(8):1004-1006. doi: 10.1016/S1470-2045(18)30513-8.
    note
    Source null
    related pmid
    30102209
    relationship
    Comment in
outcomes validated
false
pmid
29941280
provenance
batch id
c4c0356d060413f719c2
provider
NCBI PubMed ESummary
record sha256
b5257b1f356e5ef67ffe476f48083473911a6220977fb2268ed0a7df9f988d5f
response sha256
adeb6beaad718f060a94981fd9e96a2eaddc4f781839549cb3e53cba822117c0
retrieved at
2026-09-09T23:47:33.674758+00:00
publication date
display
2018 Aug
precision
month
year
2018
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29941280/
title
Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial.

Preserved source evidence · Not medical advice